These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11239185)

  • 1. Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles.
    Samsa GP; Matchar DB
    Stroke; 2001 Mar; 32(3):669-74. PubMed ID: 11239185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the analysis and interpretation of outcome measures in stroke clinical trials: lessons from the SAINT I study of NXY-059 for acute ischemic stroke.
    Koziol JA; Feng AC
    Stroke; 2006 Oct; 37(10):2644-7. PubMed ID: 16946150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proof-of-principle phase II MRI studies in stroke: sample size estimates from dichotomous and continuous data.
    ; Phan TG; Donnan GA; Davis SM; Byrnes G
    Stroke; 2006 Oct; 37(10):2521-5. PubMed ID: 16931782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials.
    Philip M; Benatar M; Fisher M; Savitz SI
    Stroke; 2009 Feb; 40(2):577-81. PubMed ID: 19074479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design.
    Muir KW
    Stroke; 2002 Jun; 33(6):1545-50. PubMed ID: 12052989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in acute ischemic stroke trials through the 20th century.
    Kidwell CS; Liebeskind DS; Starkman S; Saver JL
    Stroke; 2001 Jun; 32(6):1349-59. PubMed ID: 11387498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective agents in Acute Ischemic Stroke-A Reality Check.
    Goenka L; Uppugunduri Satyanarayana CR; S SK; George M
    Biomed Pharmacother; 2019 Jan; 109():2539-2547. PubMed ID: 30551514
    [No Abstract]   [Full Text] [Related]  

  • 9. Applying a phase II futility study design to therapeutic stroke trials.
    Palesch YY; Tilley BC; Sackett DL; Johnston KC; Woolson R
    Stroke; 2005 Nov; 36(11):2410-4. PubMed ID: 16224086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute ischemic stroke trials.
    Saver JL; Kidwell CS; Liebeskind DS; Starkman S
    Stroke; 2001 Jan; 32(1):275-8. PubMed ID: 11136948
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?
    De Keyser J; Sulter G; Luiten PG
    Trends Neurosci; 1999 Dec; 22(12):535-40. PubMed ID: 10542428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute stroke trials: strengthening the underpowered.
    Furlan AJ
    Stroke; 2002 Jun; 33(6):1450-1. PubMed ID: 12052967
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting neuroprotection clinical trials to ischemic stroke patients with potential to benefit from therapy.
    Weir CJ; Kaste M; Lees KR;
    Stroke; 2004 Sep; 35(9):2111-6. PubMed ID: 15243146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke.
    Logallo N; Kvistad CE; Thomassen L
    CNS Drugs; 2015; 29(10):811-8. PubMed ID: 26387127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The failure of animal models of neuroprotection in acute ischemic stroke to translate to clinical efficacy.
    Xu SY; Pan SY
    Med Sci Monit Basic Res; 2013 Jan; 19():37-45. PubMed ID: 23353570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions.
    Gladstone DJ; Black SE; Hakim AM;
    Stroke; 2002 Aug; 33(8):2123-36. PubMed ID: 12154275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial.
    Heiss WD; Brainin M; Bornstein NM; Tuomilehto J; Hong Z;
    Stroke; 2012 Mar; 43(3):630-6. PubMed ID: 22282884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial.
    Gharagozli K; Harandi AA; Houshmand S; Akbari N; Muresanu DF; Vester J; Winter S; Moessler H
    J Med Life; 2017; 10(3):153-160. PubMed ID: 29075343
    [No Abstract]   [Full Text] [Related]  

  • 19. NXY-059 for acute ischemic stroke: the promise of neuroprotection is finally realized?
    Fisher M
    Stroke; 2006 Oct; 37(10):2651-2. PubMed ID: 16946143
    [No Abstract]   [Full Text] [Related]  

  • 20. [Past, present and future of neuroprotection].
    Mracek J
    Cas Lek Cesk; 2010; 149(12):586-90. PubMed ID: 21387585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.